Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it completed the previously-disclosed acquisition of ACell, Inc.
“Acquiring ACell and its proprietary MatriStem UBM™ technologies will enable Integra to provide more comprehensive complex wound management solutions to address our customers’ most pressing clinical challenges,” said Peter Arduini, president and CEO, Integra LifeSciences. “Together with ACell colleagues, we look forward to continuing to advance wound care innovations for our customers and patients.”
Sullivan & Cromwell LLP is acting as legal advisor to Integra.
Source: Biospace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
